Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023
September 27, 2023 09:18 ET
|
Pyxis Oncology
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology to Participate in Two Upcoming Investment Conferences
August 31, 2023 16:01 ET
|
Pyxis Oncology
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today...
Pyxis Oncology Successfully Completes Acquisition of Apexigen
August 23, 2023 08:35 ET
|
Pyxis Oncology
Transaction adds a validated antibody-discovery platform, Phase 2 candidate and royalty stream Company positioned as a leader in next-generation, end-to-end Antibody-Drug Conjugate (“ADC”) creation...
Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update
August 11, 2023 07:00 ET
|
Pyxis Oncology
Third dose cohort initiated in Phase 1 trial of PYX-201, Pyxis Oncology's first ADC product candidate Preliminary data from two Phase 1 trials on track for late 2023 to early 2024 Apexigen...
Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference
August 01, 2023 16:01 ET
|
Pyxis Oncology
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2023 17:00 ET
|
Pyxis Oncology
BOSTON, June 30, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers,...
Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs
May 30, 2023 08:30 ET
|
Pyxis Oncology
First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC)...
Pyxis Oncology to Acquire Apexigen
May 24, 2023 06:45 ET
|
Pyxis Oncology
Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of...
Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update
May 11, 2023 07:00 ET
|
Pyxis Oncology
Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash...
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2023 17:00 ET
|
Pyxis Oncology
CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat...